FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026
Clinical Lymphoma Myeloma and Leukemia · 2026-10
DOI: 10.1016/j.clml.2026.10.011 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Changnian Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: changnianli330@163.com. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: changnianli330@163.com.
- First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: jingjingpan0929@163.com.
Zitieren
APA
Li, C., & Pan, J. (2026). FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.011
Vancouver
Li C, Pan J. FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.011
BibTeX
@article{Li2026,
author = {Li, Changnian and Pan, Jingjing},
title = {FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.10.011}
}
EUVIMED